Form 4: CARLSMED Director Philip Young Boosts Stake with IPO Purchases and RSU Award

CARLSMED Director Philip M. Young reported significant acquisitions of company stock, including purchases in the initial public offering and an award of restricted stock units.

Summary

• Director Philip M. Young was awarded 17,333 restricted stock units (RSUs) on July 22, 2025, which will vest in equal annual installments over three years.
• On July 24, 2025, 28,900 shares of Series B Preferred Stock held by PMY Partners LP were converted into an equal number of Common Stock shares immediately prior to the company's initial public offering (IPO).
• PMY Partners LP, for which Mr. Young is the sole general partner, purchased 6,666 shares of Common Stock in the IPO at the public offering price of $15.00 per share on July 24, 2025.
• The Young Family Trust, for which Mr. Young is a trustee, purchased 53,333 shares of Common Stock in the IPO at the public offering price of $15.00 per share on July 24, 2025.
• Following these transactions, Mr. Young beneficially owns 17,333 shares directly (unvested RSUs), 35,566 shares indirectly through PMY Partners LP, and 53,333 shares indirectly through the Young Family Trust, totaling 106,232 shares.

Sentiment

Score: 8

Explanation: The filing indicates strong insider confidence through significant purchases in the company's initial public offering and an award of restricted stock units, which aligns the director's interests with long-term company performance.

Positives

• Director Philip M. Young received an award of 17,333 restricted stock units, aligning his interests with long-term shareholder value.
• Mr. Young, through affiliated entities (PMY Partners LP and Young Family Trust), made substantial purchases totaling 59,999 shares of Common Stock in the company's initial public offering at $15.00 per share, demonstrating strong insider confidence.

Future Outlook

The awarded restricted stock units are set to vest in equal annual installments over three years, indicating a future schedule for equity compensation.

Industry Context

This filing represents standard insider transaction reporting following an initial public offering, where directors and affiliated entities often participate to demonstrate confidence and support the offering.

Related Party Transactions

• PMY Partners LP, for which Philip M. Young is the sole general partner, purchased 6,666 shares in the IPO and converted 28,900 preferred shares to common stock.
• The Young Family Trust, for which Philip M. Young is a trustee, purchased 53,333 shares in the IPO.

Stakeholder Impact

• Shareholders may view the significant insider purchases in the IPO as a positive signal of management's belief in the company's valuation and future prospects.

Next Steps

• The 17,333 restricted stock units awarded to Philip M. Young will vest in equal annual installments over three years.

Key Dates

Recommendation

The director's substantial investment in the company's initial public offering, both personally and through affiliated entities, signals strong confidence in the company's future prospects and valuation at the IPO price. This insider buying activity is generally viewed as a positive indicator for potential investors.

Keywords

CARLSMED, CARL, Insider Trading, Form 4, Stock Purchase, Restricted Stock Units, IPO, Beneficial Ownership, Director, Equity Compensation